Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Autoimmune and Oncology Drug Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CD86 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CD86 ECD-Fc Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View CD86 Products |
| Gene Delivery | CD86 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View CD86 Products |
| Benchmark Ab | Anti-CD86 (Sequence of Abatacept/Belatacept parent or clinical mAb) Recombinant positive control. |
View CD86 Products |
| Validator | CD86 siRNA Set For knockdown verification. |
View CD86 Products |
| Related Target A | CD28 Primary costimulatory receptor on T cells interacting with CD86. |
View CD28 Products |
| Related Target B | CTLA4 High-affinity coinhibitory receptor competing with CD28 for CD86 binding. |
View CTLA4 Products |
| Related Target C | CD80 Homologous B7 family ligand sharing CD28/CTLA-4 pathways. |
View CD80 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse evaluation | Human, Mouse, and Cynomolgus ortholog proteins available with >95% purity and verified sequences. |
| Subfamily counter-screening (CD80 vs CD86 selectivity) | Homolog panel proteins strictly verified by mass spectrometry and theoretical molecular weight. |
| Lack of standard positive controls | Recombinant clinical benchmark antibodies synthesized with exact sequence fidelity. |
| Target knockdown validation | Sequence-specific siRNA knockdown sets designed for high transfection efficiency. |
Live CD86/FUN1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CD86 therapeutics is intensifying, with major players shifting focus from traditional immunosuppressive fusion proteins to highly selective monoclonal antibodies and bispecific modalities. As first-generation therapies like Abatacept and Belatacept reach mature market penetration, the next wave of R&D is targeting selective CD86 blockade to preserve CD80-CTLA4 coinhibitory signaling, or leveraging CD86 as a tumor-associated antigen in hematological malignancies.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Selective mAb | Bristol Myers Squibb, Alpine Immune Sciences | Rheumatoid Arthritis, Lupus Nephritis | Selectivity Assay (Need CD86 ECD-Fc vs CD80 panel) |
| Bispecific Ab | Johnson & Johnson, Roche | Autoimmune Diseases, Solid Tumors | Heterodimer Validation (Need Cross-reactive Abs & Antigens) |
| Fusion Protein | Nuvation Bio, Boehringer Ingelheim | Transplant Rejection, Autoimmunity | High-concentration stability and binding kinetics (Need HEK293 Expressed Proteins) |